Kairos Pharma, Ltd., a privately held clinical stage biotechnology company focused on drug resistance and immunotherapy for cancer, today announced that its activated T cell therapy, KROS 201, has received FDA approval to proceed with a Phase 1 clinical trial in patients with recurrent glioblastoma, a type of brain cancer. The phase I trial is…
eTurboNews ʻatikala no ka poʻe kākau inoa wale nō. ʻO ke kau inoa ʻana FREE.
Komo ka poʻe kākau inoa ma ʻaneʻi Kaomi ma aneʻi e kau inoa FREE
Komo ka poʻe kākau inoa ma ʻaneʻi Kaomi ma aneʻi e kau inoa FREE
He aha e lawe ʻia mai kēia ʻatikala:
- , he hui biotechnology kahua hoʻomaʻamaʻa pilikino i mālama ʻia i ka kūʻē ʻana i ka lāʻau a me ka immunotherapy no ka maʻi kanesa, i kēia lā ua hoʻolaha ʻia ua loaʻa i kāna T cell therapy, KROS 201, ka ʻae ʻia e FDA e hoʻomau i kahi hoʻokolohua lapaʻau Phase 1 i nā poʻe maʻi me ka glioblastoma hou, kahi ʻano o lolo lolo.
- He manuahi ke kau inoa.
- The phase I trial is….
